156 |
Type II Endoleak After EVAR: How to Decide Intervention and How? |
Kishore Sieunarine |
Apr. 21. 16 |
155 |
Type I Endoleak After EVAR: Wait and See or What Is Best Option? |
John Robert Laird, Jr. |
Apr. 21. 16 |
154 |
Which Patients Will Benefit from Early TEVAR in Uncomplicated Acute Type B Dissection? |
Han Cheol Lee |
Apr. 21. 16 |
153 |
Is Hybrid Surgical-Endovascular Approach the Best Choice for Aortic Arch Aneurysms? |
Jihoon Kim |
Apr. 21. 16 |
152 |
Radial Access for Carotid Stenting: Why Do We Need to Develop This Technique? |
Piotr Odrowaz-Pieniazek |
Apr. 21. 16 |
151 |
CAS Should Replace CEA in Patients Eligible for Bypass Surgery with Multilevel Atherosclerosis |
Piotr Odrowaz-Pieniazek |
Apr. 21. 16 |
150 |
Does Carotid Stent Cell Design Matter?: Open vs. Closed vs. Micromesh |
Mark W. Burket |
Apr. 21. 16 |
149 |
Tailored Carotid Protection: Matching the Device to the Patient |
Jae-Hwan Lee |
Apr. 21. 16 |
148 |
Turn to Starting Line - Which Strategy for Whom?: CAS vs. CEA vs. Medical Therapy |
Robert Bersin |
Apr. 21. 16 |
147 |
A Novel Sirolimus Drug Coated Balloon Technology |
Robert Bersin |
Apr. 21. 16 |